Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986523 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BMS-986523 (Nov 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986523 | BMS 986523|BMS986523 | Limited information is currently available on BMS-986523 (Nov 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07223047 | Phase Ib/II | BMS-986523 + Pembrolizumab BMS-986523 + Gemcitabine + Nab-paclitaxel BMS-986523 BMS-986523 + Cetuximab | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | Not yet recruiting | USA | ESP | CAN | 0 |